Compare Natera Inc. Common Stock (NTRA) vs ONEOK Inc. Common Stock (OKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ONEOK Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while ONEOK Inc. Common Stock trades at $92.67 (market cap $57.98B). The key difference: Natera Inc. Common Stock and ONEOK Inc. Common Stock are close in size by market cap, and ONEOK Inc. Common Stock pays a 4.65% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ONEOK Inc. Common Stock for 5 Days on average.
| NTRA | OKE | |
|---|---|---|
Market Cap | $57.03B | $57.98B |
Volume | 1,131,157 | 3,747,355 |
Sector | Health | Energy |
52-Week High | $425.64 | $97.51 |
52-Week Low | $179.42 | $64.31 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $56.18B | $90.84B |
Dividend Yield | — | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ONEOK (OKE) trades at $93.38, up 1.48% with a bullish technical outlook and strong fundamental performance. The stock shows solid valuation metrics with P/E of 16.13 and P/S of 1.5, supported by $33.63B revenue and $3.39B net income in 2025. Recent acquisition of Brazos Midstream's assets for $4.425B expands Permian Basin presence, while quarterly dividends remain steady at $1.07 per share.
Outlook remains positive with analyst consensus target of $98.55 (5.5% upside) and no sell ratings. Key risks include integration of recent acquisition and commodity price exposure. Earnings beat expectations in 2 of last 3 quarters, with Q3 2026 results due October 27 providing next catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ONEOK Inc. Common Stock
ONEOK operates energy infrastructure for natural gas, natural gas liquids, and crude oil. Its assets include pipelines, processing facilities, storage, and related services.
Read more on OKE →
